



SCIENTIFIC AMERICAN REVIEWS THE POTENTIAL OF ABLYNX'S NANOBODIES™ AS DRUGS

GHENT, Belgium, 1 August 2005 - This month, Scientific American features a review of Ablynx's Nanobodies™ and their use as a novel class of therapeutics. A link to the on-line version of this article is included below.

<http://www.sciam.com/article.cfm?articleID=0004C949-F886-12DB-B88683414B7F0000&sc=I100322>

Ablynx continues to make rapid and substantive progress with its Nanobody™ platform and has recently successfully completed *in vivo* pre-clinical studies in three different diseases, including efficacy and immunogenicity studies in primates. First human studies will commence in the second half of next year.

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies™, a novel class of therapeutic proteins, for a range of serious human diseases. Because of their small size, unique structure and unparalleled stability, Nanobodies™ combine the advantages of conventional antibodies with key features of small-molecule drugs. Ablynx has an unrivalled patent portfolio in the field of single domain antibodies with granted composition of matter claims both in the USA and Europe. Headquartered in Ghent, Belgium, Ablynx has raised over €33 million (over US\$40 million) from a strong investor consortium including Abingworth Management (UK), Alta Partners (USA), Biotech Fund Flanders (Belgium), Gilde Investment Management (The Netherlands), GIMV (Belgium) and Sofinnova Partners (France).

To find out more about Ablynx, visit www.ablynx.com